CEVOLUTION: what one clinician is saying

Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

Screened window

Jul 23, 2026 → Oct 9, 2026

Cited window

Sep 29, 2026 → Sep 29, 2026

Retrieved

Nov 9, 2026

Title

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Patients With Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy

Registry

NCT07555938

Study IDs

CO46096 · 2025-524028-23-00

Sponsor

Hoffmann-La Roche

Design

Phase 3 · Interventional, randomized, parallel

Status

Recruiting

Enrollment

380 estimated

Registered

2026-04-29

Start

2026-06-23 actual

Primary completion

2028-10-31 estimated

Primary endpoints

• Minimal Residual Disease (MRD)-Negative Complete Response (CR) Rate
• Progression-Free Survival (PFS)

Interventions

6 registered

More on: Multiple myeloma

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –2 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: 86 sources about other trials or topics are not included.
• –The substantive views come from one interview with a speaker described in the source as involved in CEVOLUTION; they cannot establish broader clinician agreement or disagreement.
• –Public discussion was not exhaustively covered, so unnamed trial references and alternative transcriptions may be missing.

How reports are built and checked: Methods.

Last checked for new commentary Nov 9, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "CEVOLUTION" (NCT07555938), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "cevolution-nct07555938". If you cannot make requests, read https://www.erudio.com/reports/cevolution-nct07555938.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT07555938", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT07555938 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/cevolution-nct07555938.json
curl https://www.erudio.com/reports/cevolution-nct07555938.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "cevolution-nct07555938" })